|Bid||244.50 x 0|
|Ask||245.00 x 0|
|Day's range||241.90 - 245.10|
|52-week range||193.70 - 249.30|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||22.42|
|Earnings date||27 Apr 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||269.56|
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.